Literature DB >> 18235040

Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.

Ali Badiee1, Mahmoud R Jaafari, Afshin Samiei, Dina Soroush, Ali Khamesipour.   

Abstract

CpG oligodeoxynucleotides (CpG ODN) have been shown to have potent adjuvant activity for a wide range of antigens. The purpose of this study was to determine the potential benefit of using liposomes as a delivery vehicle to enhance the adjuvant activity of CpG ODN with Leishmania major stress-inducible protein 1 (LmSTI1) antigen in induction of the Th1 response in a murine model of leishmaniasis. BALB/c mice were immunized subcutaneously three times in 3-week intervals with liposomal recombinant LmSTI1 (Lip-rLmSTI1), rLmSTI1 coencapsulated with CpG ODN in a liposome (Lip-rLmSTI1-CpG ODN), rLmSTI1 plus CpG ODN in phosphate-buffered saline (PBS), rLmSTI1 plus non-CpG ODN in PBS, rLmSTI1 in PBS, empty liposome, or PBS. The intensity of infection induced by L. major promastigote challenge was measured by footpad swelling. A significant (P < 0.001) inhibition of infection in mice immunized with Lip-rLmSTI1-CpG ODN was shown compared to the other groups, and no parasite was detected in the spleens of this group 14 weeks after challenge. The highest immunoglobulin G2a (IgG2a) titer and the highest IgG2a/IgG1 ratio were also shown in the sera of mice immunized with Lip-rLmSTI1-CpG ODN before and 14 weeks after challenge. The results indicated the superiority of CpG ODN in its liposomal form over its soluble form to induce the Th1 response when used in association with rLmSTI1 antigen. It seems that using a liposome delivery system carrying CpG ODN as an adjuvant coencapsulated with Leishmania antigen plays an important role in vaccine development strategies against leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18235040      PMCID: PMC2292650          DOI: 10.1128/CVI.00413-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  45 in total

Review 1.  CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function.

Authors:  R S Chu; D Askew; C V Harding
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

2.  CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.

Authors:  R D Weeratna; C L Brazolot Millan; M J McCluskie; H L Davis
Journal:  FEMS Immunol Med Microbiol       Date:  2001-12

Review 3.  Il-12: keeping cell-mediated immunity alive.

Authors:  A Y Park; P Scott
Journal:  Scand J Immunol       Date:  2001-06       Impact factor: 3.487

Review 4.  Liposomes to target the lymphatics by subcutaneous administration.

Authors:  C Oussoren; G Storm
Journal:  Adv Drug Deliv Rev       Date:  2001-08-23       Impact factor: 15.470

Review 5.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

6.  Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.

Authors:  Mahmoud R Jaafari; Attieh Ghafarian; Ahsan Farrokh-Gisour; Afshin Samiei; Masoumeh Tavassoti Kheiri; Fereidoun Mahboudi; Farzaneh Barkhordari; Ali Khamesipour; W Robert McMaster
Journal:  Vaccine       Date:  2006-05-11       Impact factor: 3.641

7.  A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.

Authors:  K Yamakami; S Akao; M Sato; Y Nitta; J Miyazaki; T Tadakuma
Journal:  Parasitol Int       Date:  2001-07       Impact factor: 2.230

8.  The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.

Authors:  S Méndez; S Gurunathan; S Kamhawi; Y Belkaid; M A Moga; Y A Skeiky; A Campos-Neto; S Reed; R A Seder; D Sacks
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

9.  Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

Authors:  A Campos-Neto; R Porrozzi; K Greeson; R N Coler; J R Webb; Y A Seiky; S G Reed; G Grimaldi
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

10.  The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.

Authors:  Mahmoud R Jaafari; Ali Badiee; Ali Khamesipour; Afshin Samiei; Dina Soroush; Masoumeh Tavassoti Kheiri; Farzaneh Barkhordari; W Robert McMaster; Fereidoun Mahboudi
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

View more
  12 in total

1.  CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.

Authors:  Suman Gupta; Shraddha A Sane; Nishi Shakya; Preeti Vishwakarma; W Haq
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 2.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

3.  Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.

Authors:  Vahid Heravi Shargh; Mahmoud Reza Jaafari; Ali Khamesipour; Seyed Amir Jalali; Hengameh Firouzmand; Azam Abbasi; Ali Badiee
Journal:  Parasitol Res       Date:  2012-01-06       Impact factor: 2.289

4.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

Review 5.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

6.  Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Authors:  Jesús Arenas; Harry van Dijken; Betsy Kuipers; Hendrik Jan Hamstra; Jan Tommassen; Peter van der Ley
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

7.  Liposomes and nanotechnology in drug development: focus on oncotargets.

Authors:  Tomohiro Kozako; Naomichi Arima; Makoto Yoshimitsu; Shin-Ichro Honda; Shinji Soeda
Journal:  Int J Nanomedicine       Date:  2012-09-14

8.  Toll-like receptors in leishmania infections: guardians or promoters?

Authors:  Marilia S Faria; Flavia C G Reis; Ana Paula C A Lima
Journal:  J Parasitol Res       Date:  2012-03-15

9.  Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.

Authors:  Ensieh Golali; Mahmoud Reza Jaafari; Ali Khamesipour; Azam Abbasi; Zahra Saberi; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2012-09       Impact factor: 2.699

10.  Differential Immune Response against Recombinant Leishmania donovani Peroxidoxin 1 and Peroxidoxin 2 Proteins in BALB/c Mice.

Authors:  Nada S Daifalla; Abebe Genetu Bayih; Lashitew Gedamu
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.